BioTime, Inc. (NYSEAMERICAN:BTX)’s share price fell 5.8% during mid-day trading on Monday . The stock traded as low as $1.11 and last traded at $1.14. 587,290 shares traded hands during trading, a decline of 34% from the average session volume of 889,811 shares. The stock had previously closed at $1.21.

Several research firms have issued reports on BTX. Zacks Investment Research downgraded shares of BioTime from a “strong-buy” rating to a “hold” rating in a report on Tuesday. HC Wainwright set a $4.00 price objective on shares of BioTime and gave the company a “buy” rating in a report on Thursday, May 2nd. Raymond James decreased their price objective on shares of BioTime from $6.00 to $5.00 and set an “outperform” rating on the stock in a report on Monday, March 18th. Maxim Group set a $3.00 price objective on shares of BioTime and gave the company a “buy” rating in a report on Friday, February 15th. Finally, Dawson James began coverage on shares of BioTime in a report on Thursday, February 7th. They set a “buy” rating on the stock. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the company. BioTime presently has an average rating of “Buy” and a consensus target price of $3.46.

BioTime (NYSEAMERICAN:BTX) last posted its quarterly earnings results on Thursday, May 9th. The biotechnology company reported $0.30 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.06) by $0.36. The business had revenue of $0.93 million during the quarter, compared to analysts’ expectations of $0.66 million.

Several large investors have recently bought and sold shares of BTX. American International Group Inc. grew its position in BioTime by 22.1% in the first quarter. American International Group Inc. now owns 71,975 shares of the biotechnology company’s stock valued at $94,000 after acquiring an additional 13,020 shares in the last quarter. Raymond James Financial Services Advisors Inc. grew its holdings in BioTime by 39.7% during the first quarter. Raymond James Financial Services Advisors Inc. now owns 47,068 shares of the biotechnology company’s stock worth $62,000 after acquiring an additional 13,383 shares during the period. Voya Investment Management LLC grew its holdings in BioTime by 42.3% during the first quarter. Voya Investment Management LLC now owns 46,234 shares of the biotechnology company’s stock worth $61,000 after acquiring an additional 13,738 shares during the period. Rhumbline Advisers grew its holdings in BioTime by 11.4% during the first quarter. Rhumbline Advisers now owns 142,796 shares of the biotechnology company’s stock worth $187,000 after acquiring an additional 14,579 shares during the period. Finally, The Manufacturers Life Insurance Company grew its holdings in BioTime by 22.1% during the first quarter. The Manufacturers Life Insurance Company now owns 81,690 shares of the biotechnology company’s stock worth $107,000 after acquiring an additional 14,802 shares during the period.

ILLEGAL ACTIVITY WARNING: This news story was first posted by Marea Informative and is the property of of Marea Informative. If you are accessing this news story on another site, it was copied illegally and reposted in violation of United States and international trademark & copyright laws. The legal version of this news story can be read at https://www.mareainformativa.com/news/2019/05/15/biotime-btx-shares-down-5-8.html.

About BioTime (NYSEAMERICAN:BTX)

BioTime, Inc, a clinical-stage biotechnology company, focuses on developing and commercializing therapies for the treatment of degenerative diseases in the United States and internationally. The company's lead product candidates include OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa multicenter trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.

Read More: Book Value Per Share – BVPS

Receive News & Ratings for BioTime Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTime and related companies with MarketBeat.com's FREE daily email newsletter.